MOTS-c users may notice subtle improvements in energy levels during exercise
This can lead to some super cool before and after photos
Upon reviewing those 400,000 posts, nearly 70,000 people reported taking a GLP-1 medication (semaglutide or tirzepatide)
Dual GLP-1/glucagon receptor agonists, including mazdutide, integrate appetite suppression with increased energy expenditure and fat oxidation, while triple GLP-1/GIP/glucagon agonists, such as retatrutide, further augment these mechanisms through multi-pathway receptor engagement
Early assessment can be helpful in understanding available care options
ZY: Investigation, Writing review & editing